{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:12:46Z","timestamp":1791105166427,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T00:00:00Z","timestamp":1384128000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T00:00:00Z","timestamp":1384128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>The long-term safety and therapeutic response of sodium oxybate (SXB) in fibromyalgia syndrome (FM) patients were assessed for a combined period of up to 1 year in a prospective, multicenter, open-label, extension study in patients completing 1 of 2 phase 3 randomized, double-blind, controlled, 14-week trials that examined the efficacy and safety of SXB 4.5 g, SXB 6 g, and placebo for treatment of FM.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>This extension study comprised an additional 38 weeks of treatment and was carried out at 130 clinical sites in 7 countries. Initial entry criteria for the previous 2 double-blind clinical trials required that patients aged \u2265 18 years met the American College of Rheumatology 1990 criteria for FM, had a body mass index (BMI) &lt; 40 kg\/m<jats:sup>2<\/jats:sup>, and had a score \u2265 50 on a 100-mm pain visual analog scale (VAS) at baseline. All patients began treatment in the extension study with SXB 4.5 g\/night (administered in 2 equally divided doses) for at least 1 week, followed by possible serial 1.5 g\/night dose increases to 9 g\/night (maximum) or reductions to 4.5 g\/night (minimum).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Of the 560 FM patients enrolled in this extension study, 319 (57.0%) completed the study. The main reason for early discontinuation was adverse events (AEs; 23.0% of patients). Patients were primarily middle-aged (mean 46.9\u2009\u00b1\u200910.8 years), female (91.1%), white (91.4%), with a mean duration of FM symptoms of 9.9\u2009\u00b1\u20098.7 years. Serious AEs were experienced by 3.6% of patients. The most frequently reported AEs (incidence \u2265 5% at any dose or overall) were nausea, headache, dizziness, nasopharyngitis, vomiting, sinusitis, diarrhea, anxiety, insomnia, influenza, somnolence, upper respiratory tract infection, muscle spasms, urinary tract infection, and gastroenteritis viral. Maintenance of SXB therapeutic response was demonstrated with continued improvement from controlled-study baseline in pain VAS, Fibromyalgia Impact Questionnaire (FIQ) total scores, and other measures. Responder analyses showed that 68.8% of patients achieved \u2265 30% reduction in pain VAS and 69.7% achieved \u2265 30% reduction in FIQ total score at study endpoint.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>The long-term safety profile of SXB in FM patients was similar to that in the previously reported controlled clinical trials. Improvement in pain and other FM clinical domains was maintained during long-term use.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial registration<\/jats:title>\n                        <jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/show\/NCT00423605\">NCT00423605<\/jats:ext-link>.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4375","type":"journal-article","created":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T02:00:51Z","timestamp":1384135251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia"],"prefix":"10.1186","volume":"15","author":[{"given":"Michael","family":"Spaeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cayetano","family":"Alegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyu Grace","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane R","family":"Guinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alvarez-Horine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin Jon","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Sodium Oxybate Fibromyalgia Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,11]]},"reference":[{"key":"4043_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/art.1780330203","volume":"33","author":"F Wolfe","year":"1990","unstructured":"Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum. 1990, 33: 160-172.","journal-title":"Arthritis Rheum"},{"key":"4043_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010, 62: 600-610.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4043_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1300\/J094v11n04_02","volume":"11","author":"AK Jain","year":"2003","unstructured":"Jain AK, Carruthers BM, van de Sande MI, Barron SR, Donaldson CCS, Dunne JV, Gingrich E, Heffez DS, Leung FY-K, Malone DG, Romano TJ, Russell IJ, Saul D, Seibel DG: Fibromyalgia syndrome: Canadian clinical working case definition, diagnostic, and treatment protocols\u2014a consensus document. J Musculoskelet Pain. 2003, 11: 3-107.","journal-title":"J Musculoskelet Pain"},{"key":"4043_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/art.1780380104","volume":"38","author":"F Wolfe","year":"1995","unstructured":"Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995, 38: 19-28.","journal-title":"Arthritis Rheum"},{"key":"4043_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.1780400905","volume":"40","author":"F Wolfe","year":"1997","unstructured":"Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB: Health status and disease severity in fibromyalgia. Results of a six-center longitudinal study. Arthritis Rheum. 1997, 40: 1571-1579.","journal-title":"Arthritis Rheum"},{"key":"4043_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1157\/13127286","volume":"131","author":"C Alegre De Miquel","year":"2008","unstructured":"Alegre De Miquel C, Sellas Fern\u00e1ndez A: Fibromyalgia: feeling and pain. Med Clin (Barc). 2008, 131: 503-504.","journal-title":"Med Clin (Barc)"},{"key":"4043_CR7","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.3899\/jrheum.090367","volume":"36","author":"P Mease","year":"2009","unstructured":"Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA, OMERACT Fibromyalgia Working Group: Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009, 36: 2318-2329.","journal-title":"J Rheumatol"},{"key":"4043_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.rdc.2009.05.002","volume":"35","author":"EH Choy","year":"2009","unstructured":"Choy EH, Mease PJ: Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). Rheum Dis Clin North Am. 2009, 35: 329-337.","journal-title":"Rheum Dis Clin North Am"},{"key":"4043_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pain.2010.03.034","volume":"150","author":"S Perrot","year":"2010","unstructured":"Perrot S, Bouhassira D, Fermanian J, Cercle d\u2019Etude de la Douleur en Rhumatologie: Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain. 2010, 150: 250-256.","journal-title":"Pain"},{"key":"4043_CR10","volume-title":"Eli Lilly and Company, Indianapolis, IN","author":"Cymbalta\u00ae (duloxetine hydrochloride) delayed-release capsules prescribing information","year":"2011","unstructured":"Cymbalta\u00ae (duloxetine hydrochloride) delayed-release capsules prescribing information: Eli Lilly and Company, Indianapolis, IN. 2011,http:\/\/pi.lilly.com\/us\/cymbalta-pi.pdf,"},{"key":"4043_CR11","volume-title":"Forest Pharmaceuticals, St. Louis, MO","author":"Savella\u00ae (milnacipran hydrochloride) prescribing information","year":"2009","unstructured":"Savella\u00ae (milnacipran hydrochloride) prescribing information: Forest Pharmaceuticals, St. Louis, MO. 2009,http:\/\/www.frx.com\/pi\/Savella_pi.pdf,"},{"key":"4043_CR12","volume-title":"Pfizer, Inc., New York, NY","author":"Lyrica\u00ae (pregabalin) capsules prescribing information","year":"2011","unstructured":"Lyrica\u00ae (pregabalin) capsules prescribing information: Pfizer, Inc., New York, NY. 2011,http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=561,"},{"key":"4043_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.clinthera.2012.03.003","volume":"34","author":"LM Arnold","year":"2012","unstructured":"Arnold LM, Emir B, Murphy TK, Zeiher BG, Pauer L, Scott G, Petersel D: Safety profile and tolerability of up to 1\u00a0year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin Ther. 2012, 34: 1092-1102.","journal-title":"Clin Ther"},{"key":"4043_CR14","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3899\/jrheum.101025","volume":"38","author":"JC Branco","year":"2011","unstructured":"Branco JC, Cherin P, Montagne A, Bouroubi A: Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol. 2011, 38: 1403-1412.","journal-title":"J Rheumatol"},{"key":"4043_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/AJP.0b013e31819be587","volume":"25","author":"AS Chappell","year":"2009","unstructured":"Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D\u2019Souza DN, Moldofsky H: A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain. 2009, 25: 365-375.","journal-title":"Clin J Pain"},{"key":"4043_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.semarthrit.2008.11.001","volume":"39","author":"PJ Mease","year":"2010","unstructured":"Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, Walker DJ, Chappell AS: Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum. 2010, 39: 454-464.","journal-title":"Semin Arthritis Rheum"},{"key":"4043_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1526-4637.2009.00755.x","volume":"11","author":"DL Goldenberg","year":"2010","unstructured":"Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM: Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 2010, 11: 180-194.","journal-title":"Pain Med"},{"key":"4043_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejpain.2009.01.006","volume":"14","author":"W Hauser","year":"2010","unstructured":"Hauser W, Thieme K, Turk DC: Guidelines on the management of fibromyalgia syndrome\u2014a systematic review. Eur J Pain. 2010, 14: 5-10.","journal-title":"Eur J Pain"},{"key":"4043_CR19","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/keq354","volume":"50","author":"W Hauser","year":"2011","unstructured":"Hauser W, Petzke F, Uceyler N, Sommer C: Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford). 2011, 50: 532-543.","journal-title":"Rheumatology (Oxford)"},{"key":"4043_CR20","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/rheumatology\/ken317","volume":"47","author":"B Nishishinya","year":"2008","unstructured":"Nishishinya B, Urrutia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, Darko G: Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford). 2008, 47: 1741-1746.","journal-title":"Rheumatology (Oxford)"},{"key":"4043_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","volume":"11","author":"W Hauser","year":"2007","unstructured":"Hauser W, Petzke F, Sommer C: Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2007, 11: 505-521.","journal-title":"J Pain"},{"key":"4043_CR22","first-page":"CD010292","volume":"1","author":"W Hauser","year":"2013","unstructured":"Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B: Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013, 1: CD010292-","journal-title":"Cochrane Database Syst Rev"},{"key":"4043_CR23","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3899\/jrheum.110026","volume":"38","author":"B Walitt","year":"2011","unstructured":"Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Hauser W, Wolfe F: The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol. 2011, 38: 2238-2246.","journal-title":"J Rheumatol"},{"key":"4043_CR24","volume-title":"Jazz Pharmaceuticals, Inc., Palo Alto, CA","author":"Xyrem\u00ae (sodium oxybate) oral solution US prescribing information","year":"2005","unstructured":"Xyrem\u00ae (sodium oxybate) oral solution US prescribing information: Jazz Pharmaceuticals, Inc., Palo Alto, CA. 2005,http:\/\/www.xyrem.com\/images\/XYREM_PI.pdf,"},{"key":"4043_CR25","volume-title":"European Union Summary of Product Characteristics","author":"Xyrem\u00ae (sodium oxybate) 500 mg\/mL oral solution","year":"2005","unstructured":"Xyrem\u00ae (sodium oxybate) 500 mg\/mL oral solution: European Union Summary of Product Characteristics. 2005,http:\/\/ec.europa.eu\/health\/documents\/community-register\/2005\/2005101310028\/anx_10028_en.pdf,"},{"key":"4043_CR26","volume-title":"Canadian Product Monograph, Valeant Canada Ltd","author":"Xyrem\u00ae (sodium oxybate) oral solution","year":"2009","unstructured":"Xyrem\u00ae (sodium oxybate) oral solution: Canadian Product Monograph, Valeant Canada Ltd. 2009,http:\/\/webprod5.hc-sc.gc.ca\/dpd-bdpp\/dispatch-repartition.do?lang=eng,"},{"key":"4043_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.sleep.2009.05.004","volume":"10","author":"J Black","year":"2009","unstructured":"Black J, Pardi D, Hornfeldt CS, Inhaber N: The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009, 10: 829-835.","journal-title":"Sleep Med"},{"key":"4043_CR28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5664\/jcsm.27994","volume":"6","author":"J Black","year":"2010","unstructured":"Black J, Pardi D, Hornfeldt CS, Inhaber N: The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010, 6: 596-602.","journal-title":"J Clin Sleep Med"},{"key":"4043_CR29","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.3899\/jrheum.091041","volume":"37","author":"H Moldofsky","year":"2010","unstructured":"Moldofsky H, Inhaber NH, Guinta DR, Alvarez-Horine SB: Effects of sodium oxybate on sleep physiology and sleep\/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol. 2010, 37: 2156-2166.","journal-title":"J Rheumatol"},{"key":"4043_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/art.24142","volume":"60","author":"IJ Russell","year":"2009","unstructured":"Russell IJ, Perkins AT, Michalek JE, Oxybate SXB-26 Fibromyalgia Syndrome Study Group: Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 2009, 60: 299-309.","journal-title":"Arthritis Rheum"},{"key":"4043_CR31","first-page":"449","volume":"69","author":"E Choy","year":"2010","unstructured":"Choy E, Alegre C, Sarzi-Puttini P, van Seventer R, Wang YG, Guinta D, Lai C, Bennett R, Sodium Oxybate in Fibromyalgia 06\u2013009 Study Group: The effects of sodium oxybate on sleep disturbance, fatigue, and functioning in fibromyalgia: results from a phase 3, randomized, double-blind, placebo-controlled international trial [abstract]. Ann Rheum Dis. 2010, 69: 449-","journal-title":"Ann Rheum Dis"},{"key":"4043_CR32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.pain.2010.12.022","volume":"152","author":"IJ Russell","year":"2011","unstructured":"Russell IJ, Holman AJ, Swick TJ, Alvarez-Horine S, Wang YG, Guinta D, Sodium Oxybate 06\u2013008 FM Study Group: Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. Pain. 2011, 152: 1007-1017.","journal-title":"Pain"},{"key":"4043_CR33","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/annrheumdis-2011-200418","volume":"71","author":"M Spaeth","year":"2012","unstructured":"Spaeth M, Bennett RM, Benson BA, Wang YG, Lai C, Choy EH: Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Ann Rheum Dis. 2012, 71: 935-942.","journal-title":"Ann Rheum Dis"},{"key":"4043_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"RH Dworkin","year":"2005","unstructured":"Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L: IMMPACT: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005, 113: 9-19.","journal-title":"Pain"},{"key":"4043_CR35","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3899\/jrheum.081090","volume":"36","author":"RM Bennett","year":"2009","unstructured":"Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB: Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009, 36: 1304-1311.","journal-title":"J Rheumatol"},{"key":"4043_CR36","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998, 59: 22-33.","journal-title":"J Clin Psychiatry"},{"key":"4043_CR37","volume-title":"BDI-II: Beck Depression Inventory Manual \u2013 (2nd Edition)","author":"A Beck","year":"1996","unstructured":"Beck A, Steer RA, Brown GK: BDI-II: Beck Depression Inventory Manual \u2013 (2nd Edition). 1996, San Antonio: The Psychological Corporation, Harcourt Brace & Company"},{"key":"4043_CR38","first-page":"728","volume":"18","author":"CS Burckhardt","year":"1991","unstructured":"Burckhardt CS, Clark SR, Bennett RM: The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991, 18: 728-733.","journal-title":"J Rheumatol"},{"key":"4043_CR39","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM 76\u2013338)","author":"W Guy","year":"1976","unstructured":"Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM 76\u2013338). 1976, Rockville, MD: National Institute of Mental Health"},{"key":"4043_CR40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483.","journal-title":"Med Care"},{"key":"4043_CR41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/sleep\/20.4.278","volume":"20","author":"TE Weaver","year":"1997","unstructured":"Weaver TE, Laizner AM, Evans LK, Maislin G, Chugh DK, Lyon K, Smith PL, Schwartz AR, Redline S, Pack AI, Dinges DF: An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep. 1997, 20: 835-843.","journal-title":"Sleep"},{"key":"4043_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.04.012","volume":"104","author":"LP Carter","year":"2009","unstructured":"Carter LP, Pardi D, Gorsline J, Griffiths RR: Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend. 2009, 104: 1-10.","journal-title":"Drug Alcohol Depend"},{"key":"4043_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.1790070108","volume":"7","author":"CS Burckhardt","year":"1994","unstructured":"Burckhardt CS, O\u2019Reilly CA, Wiens AN, Clark SR, Campbell SM, Bennett RM: Assessing depression in fibromyalgia patients. Arthritis Care Res. 1994, 7: 35-39.","journal-title":"Arthritis Care Res"},{"key":"4043_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2474-7-4","volume":"7","author":"A Kassam","year":"2006","unstructured":"Kassam A, Patten SB: Major depression, fibromyalgia and labour force participation: a population-based cross-sectional study. BMC Musculoskelet Disord. 2006, 7: 4-","journal-title":"BMC Musculoskelet Disord"},{"key":"4043_CR45","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1002\/art.27623","volume":"62","author":"L Dreyer","year":"2010","unstructured":"Dreyer L, Kendall S, Danneskiold-Sams\u00f8e B, Bartels EM, Bliddal H: Mortality in a cohort of Danish patients with fibromyalgia: increased frequency of suicide. Arthritis Rheum. 2010, 62: 3101-3108.","journal-title":"Arthritis Rheum"},{"key":"4043_CR46","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/rheumatology\/ker203","volume":"50","author":"EP Calandre","year":"2011","unstructured":"Calandre EP, Vilchez JS, Molina-Barea R, Tovar MI, Garcia-Leiva JM, Hidalgo J, Rodriguez-Lopez CM, Rico-Villademoros F: Suicide attempts and risk of suicide in patients with fibromyalgia: a survey in Spanish patients. Rheumatology (Oxford). 2011, 50: 1889-1893.","journal-title":"Rheumatology (Oxford)"},{"key":"4043_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/acr.20301","volume":"63","author":"F Wolfe","year":"2011","unstructured":"Wolfe F, Hassett AL, Walitt B, Michaud K: Mortality in fibromyalgia: a study of 8,186 patients over thirty-five years. Arthritis Care Res (Hoboken). 2011, 63: 94-101.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4043_CR48","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.sleep.2008.05.012","volume":"10","author":"AM Husain","year":"2009","unstructured":"Husain AM, Ristanovic RK, Bogan RK: Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009, 10: 661-663.","journal-title":"Sleep Med"},{"key":"4043_CR49","unstructured":"BMI Classification. [http:\/\/apps.who.int\/bmi\/index.jsp?introPage=intro_3.html]"},{"key":"4043_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jpain.2009.06.007","volume":"11","author":"JT Farrar","year":"2010","unstructured":"Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A: The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain. 2010, 11: 109-118.","journal-title":"J Pain"},{"key":"4043_CR51","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/art.27559","volume":"62","author":"LM Arnold","year":"2010","unstructured":"Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y: Efficacy and safety of milnacipran 100\u00a0mg\/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62: 2745-2756.","journal-title":"Arthritis Rheum"},{"key":"4043_CR52","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3899\/jrheum.090884","volume":"37","author":"JC Branco","year":"2010","unstructured":"Branco JC, Zachrisson O, Perrot S, Mainguy Y, Multinational Coordinator Study Group: A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol. 2010, 37: 851-859.","journal-title":"J Rheumatol"},{"key":"4043_CR53","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","volume":"30","author":"DJ Clauw","year":"2008","unstructured":"Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y: Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008, 30: 1988-2004.","journal-title":"Clin Ther"},{"key":"4043_CR54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1533-2500.2010.00403.x","volume":"11","author":"ME Geisser","year":"2011","unstructured":"Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ: A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract. 2011, 11: 120-131.","journal-title":"Pain Pract"},{"key":"4043_CR55","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.080734","volume":"36","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH: The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009, 36: 398-409.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4375\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:05:11Z","timestamp":1728381911000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,11]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["4043"],"URL":"https:\/\/doi.org\/10.1186\/ar4375","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,11]]},"assertion":[{"value":"29 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R185"}}